吉非替尼联合卡培他滨对复发转移三阴性乳腺癌的疗效分析
Clinical study of gefitinib plus capecitabine in treatment of recurrent and metastatic triple negative breast cancer
目的 观察吉非替尼联合卡培他滨对复发转移三阴性乳腺癌的疗效与安全性.方法 收集2011年1月至2016年6月间于江苏省南京鼓楼医院集团宿迁市人民医院经辅助治疗后出现复发转移的三阴性乳腺癌患者41例,根据患者的意愿分为2组,观察组给予吉非替尼联合卡培他滨治疗共24例;对照组给予卡培他滨单药口服共17例.2组均连续随访12个月,用药直至疾病进展或因毒性不可耐受.结果 观察组和对照组的客观有效率(objective response rate,ORR)分别为70.83%(17/24)和35.29%(6/17),疾病控制率(disease control rate,DCR)分别为91.67% (22/24)和64.71%(11/17),2组相比差异有统计学意义(P<0.05).2组的总体不良反应发生率相当,组间差异无统计学意义(P>0.05),患者均能耐受.结论 吉非替尼联合卡培他滨治疗复发转移三阴性乳腺癌有一定疗效,不良反应轻,部分患者能获得超过12个月的生存期,值得进一步研究.
更多Objective To evaluate the efficacy and safety of gefitinib plus capecitabine in treatment of recurrent and metastatic triple negative breast cancer.Methods From Jan.2011 to Jun.,41 patients who have recurrent and metastatic triple negative breast cancer after treated by adjuvant chemotherapy were enrolled in this study They were divided into two groups according to their wishes.The 24 cases in the experimental group were treated with gefitinib plus capecitabine.The 17 cases in the control group were treated with capecitabine.The two groups were followed up for 12 months.They were treated until the disease progression or the toxicity could not be tolerated.Results The objective response rate (ORR) in the experimental group and the control group was 70.83%(17/24) vs 35.29%(6/17).The disease control rate (DCR) in the two groups was 91.67% (22/24) vs 64.71% (11/17).The difference between the two groups was statistically significant (P<0.05).The incidence rate of adverse drug reactions in the two groups was similar (P>0.05),and the reactions were tolerable.Conclusion Gefitinib plus capecitabine is an effective and safe treatment for recurrent and metastatic triple negative breast cancer with tolerable adverse reactions,and some patients were able to survive for more than 12 months.
More- 浏览:216
- 被引:7
- 下载:84
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文